Acceleron Pharma To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of American Society of Clinical Oncology
5/15/2014 10:00:21 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported new interim data from the ongoing phase 2 clinical trial of dalantercept, an activin receptor-like kinase 1 (ALK1) inhibitor, in combination with Inlyta® (axitinib) in patients with advanced renal cell carcinoma (RCC). The interim data from the open-label Part 1 dose escalation and expansion cohorts will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Monday June 2, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by